Enhancing HIV-related heart disease risk tools with new data from the REPRIEVE trial
Official title: Enhancing cardiovascular risk prediction in HIV using novel factors in the REPRIEVE trial
Funded at Massachusetts General Hospital · NIH-11303267 · Data updated 2026-11-12
This project uses the REPRIEVE trial data to build a more accurate heart disease risk score for people living with HIV by combining biomarkers, imaging, and genetics.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | April 1, 2024 |
| Project end | February 29, 2028 |
| Funding year | 2026 |
| Award (this year) | $712,495 |
| NIH project number | 5R01HL169015-03 |
| Project ID | NIH-11303267 on NIH RePORTER |
Who could benefit from this research
✓Could help
People living with HIV who participated in the REPRIEVE trial and have imaging and biomarker data available for analysis.
✕Less likely to help
Individuals not represented in the REPRIEVE cohort or without access to the required biomarker/imaging data may not directly benefit.
What this research studies
People with HIV face a higher risk of cardiovascular disease partly due to ongoing inflammation. The study will analyze REPRIEVE data to create an HIV-specific risk score that includes inflammatory markers, immune data, imaging results, and genetic information. It will compare this new score with existing risk tools and see how well each correlates with coronary plaque as seen on CT scans. By leveraging diverse data, the project aims to produce a more precise way to identify HIV patients at higher risk for cardiovascular events and tailor prevention strategies. The work builds on a large, well-characterized cohort to inform future clinical decisions.
Why it matters
Potential benefit: A more accurate cardiovascular risk score for people with HIV could lead to better prevention and personalized care to reduce heart disease in this population.
How similar studies have gone: Previous work suggests standard risk scores underestimate HIV-related cardiovascular risk; this study aims to improve accuracy using richer data, with potential for meaningful improvements over existing tools.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Triant, Virginia Athena — Massachusetts General Hospital
- Study coordinator: Triant, Virginia Athena
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Traumatic Stress, Epigenetic Aging, and Heart Risk in Veterans
A large study using Veterans Affairs data to see if traumatic stress and faster biological aging relate to higher risk of stroke and heart disease.
-
Lifestyle plan to protect muscle and heart health for adults with obesity using GLP-1 medications
A real-world trial tests a combined nutrition and resistance-training program versus standard care for adults starting GLP-1 weight loss drugs to preserve lean mass and cardiovascular health.
-
Role of the body's natural cannabis-like system in diabetes progression and heart risk
This grant studies how the body's endocannabinoid system affects the progression from obesity to diabetes and the associated risk for cardiovascular disease in adults.
-
Community and Peer Support for Reducing Cardiovascular Risk
Aims to understand how community and peer programs can help people lower cardiovascular risk, by analyzing existing programs and how their implementation and social support influence outcomes.
-
CardioPredict ML: A smarter way to gauge heart risk before pregnancy
A machine learning tool helps identify women at risk for pregnancy-related heart problems before conception, using health records and prior pregnancy data.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.